Ethics & Informed Consent: Randomised Controlled Trial (RCT) (Brazil)
A detailed academic review of the ethical submission protocol, informed consent prerequisites, and reporting standards for conducting a Randomised Controlled Trial (RCT) within the regulatory framework of Brazil.
1. Ethical Principles & Legislative Framework
In research involving human participants, securing ethical clearance is a critical first step. For a Randomised Controlled Trial (RCT) being conducted in Brazil, study designs must align with the primary regulatory legislation: Resolution CNS 466/12 & Resolution CNS 510/16. This statutory framework ensures participant welfare, confidentiality, and voluntary involvement are protected.
National Ethics Board Clearance Pathway
In Brazil, human research is governed by the CEP/CONEP system, utilising the national Plataforma Brasil for protocol submission. Social science studies follow Resolution CNS 510/16, while biomedical research is regulated under Resolution CNS 466/12. Data collection and processing must strictly align with the Lei Geral de Proteção de Dados (LGPD), securing written informed consent (TCLE) and detailing data security measures to prevent administrative and legal penalties.
Administrative review and formal approval are managed by a local or regional Comitê de Ética em Pesquisa (CEP / CONEP System). Researchers must secure full approval or a formal exemption certificate from this board before recruiting any participants or commencing data collection.
2. Study Design Elements & Reporting Integrity
For a Randomised Controlled Trial (RCT), the review board places significant focus on methodological transparency. The application must outline the research rationale, recruitment protocols, inclusion and exclusion criteria, and data protection measures.
Study Classification: High Risk (Interventional)
This interventional trial requires strict protocol adherence, allocation concealment, robust adverse event monitoring, and emergency unblinding guidelines.
To guarantee academic integrity and reproducibility, the study report and subsequent publications should follow the internationally recognised reporting standard: CONSORT statement.
Special Directive: Interventional Study Protocols
Because this study design is classified as interventional, the Comitê de Ética em Pesquisa (CEP / CONEP System) requires pre-registration of the trial on a public clinical registry (e.g. ClinicalTrials.gov or a regional WHO-compliant database) before patient enrolment begins. A detailed adverse event reporting protocol must also be submitted.
3. Informed Consent & Information Sheet Guidelines
A robust participant information sheet and informed consent form are critical parts of the ethical application. Ensure your documentation incorporates the following components:
Design-Specific Consent Focus Areas
Disclosure of placebo controls, monitoring of adverse events, side effect profiles, and random assignment protocols.
- Plain Language Explanations: Avoid complex medical or technical terminology. Ensure readability matches the general population.
- Voluntary Participation: Explicitly state that participation is entirely voluntary and that individuals can withdraw at any time without negative consequences.
- Confidentiality & Data Controls: Explain how participant data will be anonymised or pseudonymised, who will have access to it, and how long it will be securely retained under Lei Geral de Proteção de Dados (LGPD).
- Risk/Benefit Disclosure: Clearly list any potential risks, discomforts, or direct benefits associated with participation in the study.
- Ethics Board Contact Information: Provide the contact details of the reviewing Comitê de Ética em Pesquisa (CEP / CONEP System) so participants can reach out if they have questions or concerns.
Research Ethics, Clinical Trials & Institutional Governance
Designing a study protocol for this Randomised Controlled Trial (RCT) in Brazil requires addressing complex ethical considerations in research for human participants. The oversight committee reviews trials to prevent historical clinical abuses and ensure that vulnerable populations research ethics are fully respected. Prior to any intervention, subjects must sign a comprehensive research consent form outlining potential side effects and protocols. Securing institutional review board approval from the local Comitê de Ética em Pesquisa (CEP / CONEP System) is a strict requirement before patient enrollment. Any wet-lab procedures must declare their containment ratings, keeping facilities at biosafety level 1 2 3 4 based on pathogen risk. Ethical oversight committees in Brazil audit the study's consent registry periodically to verify compliance with national legal statutes.
4. Regulatory Checklist Table
To streamline your ethical review submission, use the structured alignment checklist below:
| Requirement | Comitê de Ética em Pesquisa (CEP / CONEP System) Standard | CONSORT statement Standard |
|---|---|---|
| Consent Form | Signed and dated prior to study activity. Focus: Disclosure of placebo controls. | Fully documented recruitment and consent paths. |
| Risk Management | Comprehensive risk mitigation plan. Requires an independent Data Safety Monitoring Board (DSMB) and mandatory registration on a clinical trials registry (e.g. ClinicalTrials.gov) before first patient enrollment. | Adverse events reporting strategy. |
| Data Retention | Compliance with local data protection rules (Lei Geral de Proteção de Dados (LGPD)). | Provision of open-data options where possible. |
5. Academic & Research Infrastructure Matrix (Brazil)
The following authenticated registry lists top scientific organizations, clinical laboratories, and research hospitals in Brazil mapped via the Research Organization Registry (ROR) standards-compliance framework.
| Organization Name | Sector Type | Registry Identification |
|---|---|---|
| Instituto Vital Brazil (Brazil) | company | ROR ID |
| Petrobras (Brazil) | company | ROR IDWikidata/Wiki |
| Estácio (Brazil) | company | ROR IDWikidata/Wiki |
| Anhanguera (Brazil) | company | ROR ID |
| TOTVS (Brazil) | company | ROR ID |
| AES (Brazil) | company | ROR IDWikidata/Wiki |
| DuPont (Brazil) | company | ROR IDWikidata/Wiki |
| Embraco (Brazil) | company | ROR IDWikidata/Wiki |
| Folha (Brazil) | company | ROR IDWikidata/Wiki |
| Libbs (Brazil) | company | ROR ID |
| Brf (Brazil) | company | ROR IDWikidata/Wiki |
| Sanofi (Brazil) | company | ROR IDWikidata/Wiki |
| Meritor (Brazil) | company | ROR IDWikidata/Wiki |
| Teccampos (Brazil) | company | ROR ID |
| Biominas (Brazil) | company | ROR ID |
6. Frequently Asked Questions
How long does the review process normally take?
Review timelines depend on the volume of applications and whether your proposal qualifies for expedited review. On average, a standard review by an ethics board in Brazil takes between 4 to 8 weeks.
Can we use digital signatures for informed consent?
Yes, digital consent forms are increasingly accepted, provided the platform used is secure, authenticates the identity of the signer, and complies with local regulations such as the eIDAS or ESIGN Act, depending on country-specific rules.
Regulatory Context
Verified Funding Bodies
Funder registries and DOI configurations verified for compliance in Brazil via Crossref.
- Governo BrasilID: 501100002425 | Location: Brazil
- Ministério da EducaçãoID: 501100006366 | Location: Brazil
- IBM Research – BrazilID: 100031474 | Location: Brazil
- Chevron Brazil Upstream Frade LtdaID: 100015145 | Location: Brazil
- Repsol Sinopec BrasilID: 100031804 | Location: Brazil
- Brazilian Microbiome ProjectID: 100018052 | Location: Brazil
- Instituto ButantanID: 100018798 | Location: Brazil
- Fundação Nacional de SaúdeID: 501100016062 | Location: Brazil
- Brazilian Institute of Neuroscience and NeurotechnologyID: 100032024 | Location: Brazil
- Sociedade Brasileira de DermatologiaID: 501100013994 | Location: Brazil
Pre-Submission Warning
Do not recruit participants or initiate study procedures before receiving official written approval from your reviewing board. Ethical approvals cannot be granted retrospectively under Resolution CNS 466/12 & Resolution CNS 510/16.
